SEC Filings
Structure Therapeutics Research Costs Climb To $134.6 Million From $59 Million As Trial Spending Rises
The oral obesity drug developer expects its cash to last through 2028, excluding commercial preparation and manufacturing costs.
SEC Filings
The oral obesity drug developer expects its cash to last through 2028, excluding commercial preparation and manufacturing costs.
SEC Filings
Production beat the forecast midpoint, and Occidental paid down $1.8 billion of principal debt to reach $10.0 billion.
SEC Filings
Jane Street Capital holds most of the reported position; the group says its holdings are not intended to influence control.
SEC Filings
CRH guarantees the debt, which carries interest rates ranging from 5.375% to 6.250%.
SEC Filings
Unused bilateral capacity fell even as overall credit availability increased, with buybacks and plant investments drawing on cash.
SEC Filings
The passive ownership report covers September 30, with Goldman certifying that its holding was not intended to influence control.
SEC Filings
Banasino Establishment became the holding company's sole shareholder; the reporting entities retained conditional options for a deal.
SEC Filings
Denner will join the board in January, with prorated cash and equity pay under the company's non-employee director program.
SEC Filings
Directors oppose advance shareholder consent for preferred stock, arguing that a vote could delay defenses against rapid share purchases.
SEC Filings
SoftBank would retain majority ownership of the Sarawak project, while the partners seek more investors and cloud customers.
SEC Filings
The bank expects NYSE trading to end Wednesday at the close and Texas Stock Exchange trading to start Thursday at the open.
SEC Filings
The annual financial illustration puts net interest expense at $826 million, versus Fox's historical $274 million, before expected savings.